177Lu-HX02
/ Hexin (Suzhou) Pharmaceutical Technology
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
January 31, 2026
Phase I clinical trial to evaluate the safety, tolerability, radiation dosimetry, pharmacokinetics and preliminary efficacy of 177Lu-HX02 injection in patients with advanced malignant solid tumors
(ChiCTR)
- P1 | N=24 | Not yet recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of
New P1 trial • Solid Tumor
January 31, 2026
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Radiation Dosimetry, Pharmacokinetics, and Preliminary Efficacy of ¹⁷⁷Lu-HX02 Injection in Patients with Advanced Malignant Solid Tumors
(ChiCTR)
- P1 | N=24 | Not yet recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.
New P1 trial • Ewing Sarcoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor
1 to 2
Of
2
Go to page
1